Llwytho...
Preclinical evaluation of exemestane as a novel chemotherapy for gastric cancer
CYP19A1/aromatase (Ar) is a prognostic biomarker of gastric cancer (GCa). Ar is a critical enzyme for converting androstenedione to oestradiol in the steroidogenesis cascade. For decades, Ar has been targeted with Ar inhibitors (ARIs) in gynaecologic malignancies; however, it is unexplored in GCa. A...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | J Cell Mol Med |
|---|---|
| Prif Awduron: | , , , , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
John Wiley and Sons Inc.
2019
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6815818/ https://ncbi.nlm.nih.gov/pubmed/31557413 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.14605 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|